Cervilenz Inc. Announces Additions to the Patent Portfolio for the CerviLenz(R) Device
Patent additions for the CerviLenz device.
- (1888PressRelease) July 26, 2013 - Cervilenz Inc. has received a notice of allowance from the U.S. Patent & Trademark Office for US Application No. 13/747,331, entitled "Devices and Methods for Cervix Measurement." The allowed claims broadly cover a method of measuring the length of a cervix using the CerviLenz device.
Dean Koch, President and CEO of Cervilenz Inc. commented, "It's been an exciting month for us with publication of two important studies validating the efficacy of the CerviLenz device in high volume clinical applications, and now this important new patent. We are seeing strong physician adoption of CerviLenz driven by our small, direct selling team. Our sales success, patents, and peer reviewed research firmly establish CerviLenz as a valuable product franchise in women's health."
The CerviLenz device is used by healthcare professionals to measure the length of a woman's cervix while she is pregnant. A short cervix during pregnancy is known to be the best predictor of preterm birth risk and a key factor in determining whether intervention is necessary. The CerviLenz device, invented by an obstetrician, can be used in any healthcare setting, by a trained physician, midwife, or nurse.
About Cervilenz Inc.
Cervilenz Inc. manufactures and markets the CerviLenz® device- an innovative medical device that measures vaginal cervical length to help physicians identify and manage pregnant women at high risk for preterm birth. Founded in 2008, Cervilenz Inc. is dedicated to making a difference in the world of prematurity. The company headquarters is in Chagrin Falls, a suburb of Cleveland, Ohio. CERVILENZ is a registered trademark of the Company in the U.S. The trademark CERVILENZ is also registered via a community trademark application in the European Union. The CerviLenz device is classified under 21 CFR 884.4530(2)(a.) as a 510(k) exempt device and has its CE Mark and ISO 13485 Certification for international distribution. For more information, visit www.cervilenz.com or contact Melanie Sweeney, Vice President of Marketing (440.337.4253 or melanie ( @ ) cervilenz dot com) dot
About Preterm Birth
Preterm birth is a worldwide public health epidemic and the leading cause of infant death. Nearly 15 million babies are born preterm every year. In the United States, preterm birth affects 12% of pregnancies and its annual economic toll is $26.2 billion in health care and related costs.
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam